Mounjaro
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Pressure score
60
Momentum score
9
Why This Matters
Roche is a direct competitive threat because it has a development-stage program in Diabetes · GLP-1 (Mounjaro) and could narrow Lilly's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Stage unknown
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Moderate share risk if competitor advances before the signal sponsor establishes label leadership.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Roche's Mounjaro directly references the same indication focus (Diabetes · GLP-1) as this signal.
Source: Roche
View source documentRelated Signal
Lilly Q1 2026 Revenue Up 56%, Raises Full Year Guidance
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 2
Roche
2 competitive findings
Top program: Mounjaro
- Pressure
- 60
- Momentum
- 9
- Threat
- direct competitor
- Stage
- Stage unknown
60RocheMediumMounjaro·Stage unknown
Pfizer
1 competitive finding
Top program: Mounjaro
- Pressure
- 34
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
34PfizerLowMounjaro·Stage unknown